Press Room
Progress in Targeted and Immunotherapies
10/19/2012
A key theme at this yearâs American Society of Clinical Oncology (ASCO) Annual Meeting was the use of a treatment rationale based on driver mutations and immunotherapy approaches that have potential in multiple tumor types.
Pfizer kidney cancer drug fails as initial treatment
10/18/2012
Pfizer Inc said its kidney cancer drug did not meet the main goal of showing a statistically significant improvement in survival in a late-stage trial without the cancer getting worse.
Active surveillance provides a viable alternative to surgery for small kidney masses
10/18/2012
Active surveillance of small kidney masses is a safe and effective alternative to immediate surgery, with similar overall and cancer specific survival rates, according to a study published in the November issue of the urology journal BJUI.
Advances in advanced renal cell carcinoma from ESMO
10/18/2012
Professor Tim Eisen from Addenbrooke's Oncology Centre, Cambridge, talks to ecancer TV with Dr Bernard Escudier from Institut Gustave Roussy, France, Dr Thomas Powles from St Bartholomew Hospital, London, and Dr Thomas Hutson from Baylor Sammons Cancer Center, USA. The experts outline results from the major studies reporting at ESMO 2012 in mRCC.
WILEX AG announces results of Phase III ARISER study with RENCAREX® in clear cell renal cell carcinoma
10/17/2012
Trial did not meet its primary endpoint of median disease-free survival (DFS)
Expanding Waistlines May Contribute To Cancer Growth
10/17/2012
The authors believe they have discovered why obese cancer patients usually have poorer prognoses compared to slim people.
Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies
10/17/2012
The association of a genetic analysis that could improve the diagnostic accuracy of renal cell tumors in biopsy samples would allow better-informed therapeutic decisions.
Researchers Receive Grants from NCCN Oncology Research Program
10/16/2012
The NCCN Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib as a result of funding through the AVEO/Astellas collaboration.
Using cancer to fight cancer
10/16/2012
A new therapeutic vaccine 15 years in the making could make cancer kill itself.
Argos Therapeutics Identifies Immune Response Marker Connected to Prolonged Overall Survival in mRCC Patients Treated With AGS-003
10/15/2012
Updated Immune Analysis From Phase 2 Clinical Trial Presented at 2012 Markers in Cancer Meeting
News Feed| Powered by NeonCRM |